Inventor
Clifford R. King
Inventor
Hendersonville, NC, US
Overview
Patents· 81 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C09Dprimary
C09DCoating compositions, e.g. paints, varnishes or lacquers23%
C09BOrganic dyes or closely-related compounds for producing dyes, e.g. pigments18%
A61KPreparations for medical, dental or toiletry purposes15%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds10%
C07DHeterocyclic compounds10%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations8%
B41MPrinting, duplicating, marking, or copying processes4%
C07CAcyclic or carbocyclic compounds4%
B41JTypewriters3%
Y10TTechnical subjects covered by former us classification1%
PatentTitleYear
11,037,678Medical device with interfaces for capturing vital signs data and affirmatively skipping parameters associated with the vital signs data202110,183,001Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features20199,421,266'Safety of pseudoephedrine drug products'20169,226,925'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20168,980,880'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20158,957,067'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20158,940,729'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20158,921,386'Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties'20148,916,587'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20148,912,217'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20148,883,863'Safety of psuedoephedrine drug products'20148,859,622'Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance'20148,846,766'Abuse-deterrent methadone for the safe treatment of drug abuse and pain relief'20148,748,416'Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties'20148,716,337'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20148,716,278'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20148,653,106'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20148,653,065'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20148,586,575'Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder'20138,575,151'Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance'20138,569,330'Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties'20138,569,329'Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties'20138,476,291'Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties'20138,367,693'Opioid salts and formulations exhibiting anti-abuse anti-dose dumping properties'20138,338,444'Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties'20128,334,322'Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance'20128,329,720'Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties'20128,211,905'Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties'20128,039,461'Physical states of a pharmaceutical drug substance'20117,985,865'Phase change ink formulations, colorant formulations, and methods of forming colorants'20117,939,678'Phase change ink formulations, colorant formulations, and methods of forming colorants'20117,858,663'Physical and chemical properties of thyroid hormone organic acid addition salts'20107,772,377'Colorant compositions'20107,718,649'Physical states of a pharmaceutical drug substance'20107,619,075'Colorant compositions'20097,592,460'Colorant compositions'20097,582,687'Phase change inks'20097,572,845'Phase change inks'20097,504,446'Aqueous inks containing colored polymers'20097,345,200'Phase change ink formulations, colorant formulations, and methods of forming colorants'20087,323,595'Phase change ink formulations, colorant formulations, and methods of forming colorants'20087,304,173'Colorant compositions'20077,241,853'Printing processes employing intermediate transfer with molten intermediate transfer materials'20077,128,412'Printing processes employing intermediate transfer with molten intermediate transfer materials'20067,094,812'Colorant compositions'20067,034,185'Colorant precursor compositions'20067,022,879'Phase change ink formulations, colorant formulations, and methods of forming colorants'20066,969,759'Colorant compositions'20056,790,267'Colorant compositions'20046,764,541'Colorant compositions'20046,620,228'Isocyanate-derived materials for use in phase change ink jet inks'20036,444,018'Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts'20026,350,305'Selected polymeric furanone magenta colorants'20026,322,624'Phase change ink carrier compositions containing polyanhydride/amine adducts'20016,303,185'Overcoating of printed substrates'20016,245,135'Phase change ink composition'20016,235,094'Phase change ink formulations, colorant formulations, and methods of forming colorants'20016,221,137'Metal phthalocyanine colorants for phase change inks'20016,180,692'Phase change ink formulation with organoleptic maskant additive'20016,147,140'Phase change ink composition'20006,110,264'Phase change inks and methods of forming phase change inks'20006,057,399'Isocyanate-derived phase change ink additive for improved electronic level sensing reliability and type encoding'20006,048,925'Urethane isocyanate-derived resins for use in a phase change ink formulation'20006,042,227'Hot melt phase change ink containing Diels-Alder polymerization precursor'20006,028,138'Phase change ink formulation using urethane isocyanate-derived resins, a polyethylene wax and toughening agent'20006,018,005'Phase change ink formulation using urethane isocyanate-derived resins and a polyethylene wax'20006,015,847'Magenta phase change ink formulation containing organic sulfonic acid'20006,001,160'Phase change ink additive for improved electronic level sensing reliability and type encoding'19995,994,453'Phase change ink formulation containing a combination of a urethane resin, a mixed urethane/urea resin, a mono-amide and a polyethylene wax'19995,919,839'Phase change ink formulation using an isocyanate-derived wax and a clear ink carrier base'19995,830,942'Phase change ink formulation using a urethane and urethane/urea isocyanate-derived resins'19985,827,918'Phase change ink formulation using urea and urethane isocyanate-derived resins'19985,782,966'Isocyanate-derived materials for use in phase change ink jet inks'19985,783,658'Phase change ink formulation using a urethane isocyanate-derived resin and a urethane isocyanate-derived wax'19985,780,528'Isocyanate-derived colored resins for use in phase change ink jet inks'19985,750,604'Phase change ink formulation using a urethane isocyanate-derived resin'19985,621,022'Use of polymeric dyes in hot melt ink jet inks'19975,554,212'Waterfast high gloss hyperthermogelling aqueous phase change ink and method for use'19965,310,887'Aqueous ink composition and colorants useful therein'19945,176,745'Aqueous ink composition and colorants useful therein'19935,059,244'Fugitive colorant and washable ink compositions'1991Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1991–1994Based in Taylors, SC, US· patent location history
1996–2011Based in Salem, OR, US· patent location history
2000–2011Patents assigned to XEROX CORP (32)· patent assignee history
2004–2016Based in Hendersonville, NC, US· patent location history
2010–2016Patents assigned to PISGAH LAB INC (26)· patent assignee history
2012–2016Patents assigned to KING CLIFFORD RILEY (24)· patent assignee history
2012–2016Patents assigned to BRISTOL DAVID W (20)· patent assignee history
2012–2016Patents assigned to D AMBROSIO STEPHEN G (20)· patent assignee history
2019Based in Pisgah Forest, NC, US· patent location history
2021Based in Ithaca, NY, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| XEROX CORP | 32 | 2000–2011 |
| PISGAH LAB INC | 26 | 2010–2016 |
| KING CLIFFORD RILEYself | 24 | 2012–2016 |
| BRISTOL DAVID W | 20 | 2012–2016 |
| D AMBROSIO STEPHEN G | 20 | 2012–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Hendersonville, NC, US | 43 | 2004–2016 |
| Salem, OR, US | 32 | 1996–2011 |
| Taylors, SC, US | 3 | 1991–1994 |
| Ithaca, New York, US | 1 | 2021 |
| Pisgah Forest, NC, US | 1 | 2019 |